|Bid||128.44 x 1000|
|Ask||128.56 x 800|
|Day's Range||125.83 - 128.89|
|52 Week Range||102.10 - 144.67|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||163.41|
Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.
Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.
Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.
Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene.
Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
In October, 18 analysts are covering Alexion Pharmaceuticals (ALXN) stock. Five of them have recommended a “strong buy,” 11 have recommended a “buy,” and two have recommended a “hold.”
Alexion Pharmaceuticals’ (ALXN) total operating expenses increased from $602.4 million in the second quarter of 2017 to $1.35 billion in the second quarter of 2018. It generated operating income of $226.7 million in the second quarter of 2017. In the second quarter of 2018, it had an operating loss of $400.1 million.
Alexion Pharmaceuticals (ALXN) is a leader in complement inhibition. It focuses on hematology, nephrology, neurology, and metabolic disorders. In this series, we’ll explore its financials, valuation metrics, latest developments, and analyst recommendations.
Alexion Pharmaceuticals’ (ALXN) revenues increased $132.3 million to $1.04 billion in the second quarter of 2018 compared to the second quarter of 2017. For fiscal 2018 and fiscal 2019, Alexion Pharmaceuticals is expected to generate revenues of $4.04 billion and $4.72 billion, respectively, compared to $3.55 billion in fiscal 2017. Fiscal 2018 gross margins for its peers Abbott Laboratories (ABT), Amgen (AMGN), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to be 59.10%, 85.94%, 70.09%, 69.64%, and 79.21%, respectively.
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018, which reflected ~6% year-over-year (or YoY) growth. Portola Pharmaceuticals’ net revenues grew from $8.92 million in the first half of 2018 to $10.66 million in the first half of 2017, reflecting ~20% YoY growth.
Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the third quarter ended September 30, 2018 before the US financial markets open on October 24, 2018.
Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.
In the first half this year, Alexion Pharmaceuticals’ (ALXN) revenue grew 11% YoY (year-over-year) to $1.98 billion from $1.78 billion. Alexion’s Soliris generated revenue of $1.7 billion in H1 2018, with revenue of $800.1 million and $898.2 million in the first and second quarters, respectively.
On September 26, Alexion Pharmaceuticals (ALXN) entered into an agreement with Syntimmune, wherein Alexion will acquire Syntimmune with an upfront payment of $400.0 million. Syntimmune is also eligible for milestone payments of up to $800 million, bringing the total value of the transaction to $1.2 billion.
Alexion (ALXN) will acquire clinical-stage biotech company, Syntimmune for $1.2 billion to augment its rare disease pipeline.
NEW YORK, NY / ACCESSWIRE / September 27, 2018 / Separate positive developments sent shares of biotech stocks Aldeyra Therapeutics and Alexion Pharmaceuticals higher on Wednesday. It was encouraging phase 2b trial results from Aldeyra and acquisition news from Alexion Pharmaceuticals that had traders cheering. Aldeyra Therapeutics, Inc. shares were up nearly 35% at the close yesterday on colossal trading volume compared to usual.
The Dow initially added to its gains after the Federal Reserve raised rates but the good mood didn’t survive Fed Chief’s Jerome Powell’s press conference. …and explain why Alexion Pharmaceuticals soared to the top of the S&P 500. Stocks tried to break a two-day losing streak Wednesday but sank in the last hour of trading, following the Fed’s press conference.
Stocks gave up all their gains and closed well in the red Wednesday, after the Federal Reserve hiked interest rates by a quarter-point, as widely expected.